Details for Patent: 11,040,042

Which drugs does patent 11,040,042 protect, and when does it expire?

Patent 11,040,042 protects COSELA and is included in one NDA.

This patent has fifty-six patent family members in eighteen countries.

Summary for Patent: 11,040,042

Title:	Transient protection of normal cells during chemotherapy
Abstract:	This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
Inventor(s):	Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Assignee:	Pharmacosmos Holding AS , Pharmacosmos AS
Application Number:	US16/886,309
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,040,042
Patent Claim Types: see list of patent claims	Composition;

Drugs Protected by US Patent 11,040,042

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes	11,040,042		Y

International Family Members for US Patent 11,040,042

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2906156
Canada	2906157
Canada	2906166